Grail Inc Stock News

The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed ​to detect more than 50 cancers, sending the company's shares soaring 35% on Monday.

Grail stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday.

The biotech meets with the Food and Drug Administration this week for premarket approval of its landmark cancer blood test.

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to t...

Grail said on Friday the U.S. FDA ​plans to hold a ‌meeting of outside experts to review its multi-cancer screening test Galleri ​in September, sending its ​shares up 4% in morning ⁠trade.

MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.

Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the Year NHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri Complet...